Pharmacophore modeling, virtual and In Vitro screening for acetylcholinesterase inhibitors and their effects on Amyloid-β self-assembly

Current Computer-Aided Drug Design

Volumn 9, Issue 1, 2013, Pages 2-14

  Bag, Seema ^a   Tulsan, Rekha ^a   Sood, Abha ^a   Datta, Silpi ^a   Török, Marianna ^a  

^a UNIVERSITY OF MASSACHUSETTS BOSTON   (United States)

Author keywords

Acetylcholinesterase; AChE inhibitors; Alkaloids; Alzheimer's disease; Amyloid Self assembly; Docking; Drug bank database; Pharmacophore; Schr dinger

Indexed keywords

ALKALOIDS; COMMERCE; DIAGNOSIS; GLYCOPROTEINS; METABOLITES; NEURODEGENERATIVE DISEASES; PHARMACODYNAMICS;

ACETYLCHOLINESTERASE; ACETYLCHOLINESTERASE INHIBITORS; ALZHEIMERS DISEASE; AMYLOID Β SELF-ASSEMBLY; DOCKING; DRUG BANK DATABASE; IN-VITRO; PHARMACOPHORE MODELS; PHARMACOPHORES; SCHRÖDINGE;

SELF ASSEMBLY;

ALKALOID; AMYLOID BETA PROTEIN; CHOLINESTERASE INHIBITOR; LIGAND;

ALZHEIMER DISEASE; ARTICLE; BIOLOGICAL ACTIVITY; DRUG SCREENING; IC 50; IN VITRO STUDY; MOLECULAR DOCKING; PHARMACOPHORE; QUANTITATIVE STRUCTURE ACTIVITY RELATION; VALIDATION STUDY;

EID: 84876125479     PISSN: 15734099     EISSN: 18756697     Source Type: Journal    
DOI: 10.2174/1573409911309010002     Document Type: Article

References (63)

1. Selkoe, D.J., Ed. Biology of ß-Amyloid Precursor Protein and the Mechanism of Alzheimer's Disease; 2nd ed. Lippincott, Williams & Wilkins, Philadelphia, 1999, pp. 293-310.
2. Wetzel, R., Ed. Amyloid, Prions, and Other Protein Aggregates, in Methods in Enzymology, 309, Academic Press, 1999.
3. Ramirez-Alvarado, M.; Kelly, J.W.; Dobson, C.M., Eds. Protein Misfolding Diseases. Wiley, Hoboken, NJ, 2010.
4. Murphy, R.M. Peptide aggregation in neurodegenerative disease. Annu. Rev. Biomed. Eng., 2002, 4, 155-174.
5. Selkoe, D.J. Folding proteins in fatal ways. Nature, 2003, 426, 900-904.
6. Golde, T.E. Alzheimer disease therapy: can the amyloid cascade be halted? J. Clin. Invest., 2003, 111, 11-18.
7. Bartus, R.T.; Dean, R.L. III; Beer, B.; Lippa, A.S. The cholinergic hypothesis of geriatric memory dysfunction. Science, 1982, 217, 408-414.
8. Silman, I.; Sussman, J.L. Acetylcholinesterase: 'classical' and 'non-classical' functions and pharmacology. Curr. Opin. Pharmacol., 2005, 5, 293-302.
9. De Ferrari, G.V.; Canales, M.A.; Shin, I.; Weiner, L.M.; Silman, I.; Inestrosa, N.C. A structural motif of acetylcholinesterase that promotes amyloid β-peptide fibril formation. Biochemistry, 2001, 40, 10447-10457.
10. Bartolini, M.; Bertucci, C.; Cavrini, V.; Andrisano, V. β -Amyloid aggregation induced by human acetylcholinesterase: inhibition studies. Biochem. Pharmacol., 2003, 65, 407-416.
11. Colombres, M.; Sagal, J.P.; Inestrosa, N.C. An overview of the current and novel drugs for Alzheimer's disease with particular references to anti-cholinesterase compounds. Curr. Pharm. Des., 2004, 10, 3121-3130.
12. Sheng, R.; Lin, X.; Li, J.; Jiang, Y, Shang, Z.; Hu, Y. Design, synthesis, and evaluation of 2-phenoxy-indan-1-one derivatives as acetylcholinesterase inhibitors. Bioorg. Med. Chem. Lett., 2005, 15, 3834-3837.
13. Selkoe, D.J. Translating cell biology into therapeutic advances in Alzheimer's disease. Nature, 1999, 399, A23-A31.
14. Yankner, B.A. Mechanisms of neuronal degeneration in Alzheimer's disease. Neuron, 1996, 16, 921.
15. Larner, A.J. Cholinesterase inhibitors: beyond Alzheimer's disease. Expert Rev. Neurotherapeut., 2010, 10, 1699-1705.
16. Wollen, K.A. Alzheimer's disease: the pros and cons of pharmaceutical, nutritional, botanical, and stimulatory therapies, with a discussion of treatment strategies from the perspectives of patients and practitioners. Alt. Med. Rev., 2010, 15, 223-244.
17. Orhan, I.E.; Khan, M.T.H.; Erdem, S.A.; Kartal, M.; Sener, B. Selective cholinesterase inhibitors from Buxus sempervirens L. and their molecular docking studies. Curr. Comput. Aided Drug Des., 2011, 7, 276-286.
18. Anderson, A.C.; Wright, D.L. The design and docking of virtual compound libraries to structures of drug target. Curr. Comput. Aided Drug Des., 2005, 1, 103-127.
19. Kaur, J.; Zhang, M.Q. Molecular modelling and QSAR of reversible acetylcholinesterase inhibitors. Curr. Med. Chem., 2000, 7, 273-294.
20. Bermudez-Lugo, J. A.; Rosales-Hernandez, M.C.; Deeb, O.; Trujillo-Ferrara, J.; Correa-Basurto, J. In silico methods to assist drug developers in acetylcholinesterase inhibitor design. Curr. Med. Chem., 2011, 18, 1122-1136.
21. Krovat, E.M.; Frühwirth, K.H.; Langer, T. Pharmacophore identification, in silico screening, and virtual library design for inhibitors of the human factor Xa. J. Chem. Inf. Model., 2005, 45, 146-159.
22. Barreca, M.L.; De Luca, L.; Iraci, N.; Rao, A.; Ferro, S.; Maga, G.; Chimirri, A. Structure-based pharmacophore identification of new chemical scaffolds as non-nucleoside reverse transcriptase inhibitors. J. Chem. Inf. Model., 2007, 47, 557-562.
23. Schormann, N.; Senkovich, O.; Walker, K.; Wright, D.L.; Anderson, A.C.; Rosowsky, A.; Ananthan, S.; Shinkre, B.; Velu, S.; Chattopadhyay, D. Structure-based approach to pharmacophore identification, in silico screening and 3D-QSAR studies for inhibitors of Trypanosoma cruzi DHFR function. Proteins, 2008, 73, 889-901.
24. Sakkiah, S.; Thangapandian, S.; John, S.; Lee, K.W. Pharmacophore based virtual screening, molecular docking studies to design potent heat shock protein 90 inhibitors. Eur. J. Med. Chem., 2011, 46, 2937-2947.
25. Gao, Q.; Yang, L.; Zhu, Y. Pharmacophore based drug design approach as a practical process in drug discovery. Curr. Comput. Aided Drug Des., 2010, 6, 37-49.
26. Chaudhaery, S.S.; Roy, K.K.; Shakya, N.; Saxena, G.; Sammi, S.R.; Nazir, A.; Nath, C. Saxena, A.K. Novel carbamates as orally active acetylcholinesterase inhibitors found to improve scopolamine-induced cognition impairment: pharmacophore-based virtual screening, synthesis, and pharmacology. J. Med. Chem., 2010, 53, 6490-6505.
27. Gupta, S.; Mohan, C.G. 3D-pharmacophore model based virtual screening to identify dual-binding site and selective acetylcholinesterase inhibitors. Med. Chem. Res., 2011, 20, 1422-1430.
28. Gupta, S.; Fallarero, A.; Järvinen, P.; Karlsson, D.; Johnson, M.S.; Vuorela, P.M.; Mohan, C.G. Discovery of dual binding site acetylcholinesterase inhibitors identified by pharmacophore modeling and sequential virtual screening techniques. Bioorg. Med. Chem. Lett., 2011, 21, 1105-1112.
29. Schuster, D.; Spetea, M.; Music, M.; Rief, S.; Fink, M.; Kirchmair, J.; Schütz, J.; Wolber, D.; Langer, T.; Stuppner, H.; Schmidhammer, H.; Rollinger, J.M. Morphinans ans isoquilonines: Acetylcholinesterase inhibition, pharmacophore modeling, and interaction with opiod receptors. Bioorg. Med. Chem., 2010, 18, 5071-5080.
30. Salam, N.K.; Nuti, R.; Sherman, W. Novel method for generating structure-based pharmacophores uisng energetic analysis. J. Chem. Inf. Model., 2009, 49, 2356-2368.
31. Török, M.; Milton, S.; Kayed, R.; Wu, P.; McIntire, T.; Glabe, C.G.; Langen, R. Structural and dynamic features of Alzheimer's A? Peptide in amyloid fibrils studied by site-directed spin labeling. J. Biol. Chem., 2002, 277, 40810-40815.
32. Török, M.; Abid, M.; Mhadgut, S.C.; Török, B. organofluorine inhibitors of amyloid fibrillogenesis. Biochemistry, 2006, 45, 5377-5383.
33. Sood, A.; Abid, M.; Hailemichael, S.; Foster, M.; Török, B.; Török, M. Effect of chirality of small molecule organofluorine inhibitors of amyloid self-assembly on inhibitor potency. Bioorg. Med. Chem. Lett., 2009, 19, 6931-6934.
34. Sood, A.; Abid, M.; Sauer, C.; Hailemichael, S.; Foster, M.; Török, B.; Török, M. Effect of chirality of small molecule organofluorine inhibitors of amyloid self-assembly on inhibitor potency. Bioorg. Med. Chem. Lett., 2010, 21, 2044-2047.
35. Borkin, D.; Morzhina, E.; Datta, S.; Rudnitskaya, A.; Sood, A.; Török, M.; Török, B. Heteropoly acid-catalyzed microwave-assisted three-component aza-Diels-Alder cyclizations: diastereo-selective synthesis of potential drug candidates for Alzheimer's disease. Org. Biomol. Chem., 2011, 9, 1394-1401.
36. Drug Bank Database, http://www.drugbank.ca/accessed: 05/26/2011.
37. Protein Data Bank: http://www.pdb.orgaccessed: 05/10/2011.
38. Piazzi, L.; Cavalli, A.; Colizzi, F.; Belluti, F.; Bartolini, M.; Mancini, F.; Recanatini, M.; Adrisano, V.; Rampa, A. Multi-target-directed coumarin derivatives: hAChE and BACE1 inhibitors as potential anti-Alzheimer compounds. Bioorg. Med. Chem. Lett., 2008, 18, 423-426.
39. Piazzi, L.; Cavalli, A.; Belluti, F.; Bisi, A.; Gobbi, S.; Rizzo, S.; Bartolini, M.; Adrisano, V.; Recanatini, M.; Rampa, A. Extensive SAR and computational Studies of 3-{4-[(benzylmethylamino) methyl]phenyl}-6,7-dimethoxy-2H-2-chromenone (AP2238) derivatives. J. Med. Chem., 2007, 50, 4250-4254.
40. Bolognesi, M.L.; Cavalli, A.; Valgimigli, L.; Bartolini, M.; Rosini, M.; Andrisano, V.; Recanatini, M.; Melchiorre, C. Multi-target-directed drug design strategy: from a dual binding site acetylcholinesterase inhibitor to a trifunctional compound against Alzheimer's Disease. J. Med. Chem., 2007, 50, 6446-6449.
41. Bolognesi, M.L.; Andrisano, V.; Bartolini, M.; Banzi, R.; Nelchiorre, C. Propidium-based polyamine ligands as potent inhibitors of acetylcholinesterase and acetylcholinestresae-induced amyloid-β aggregation. J. Med. Chem., 2005, 48, 24-27.
42. Belluti, F.; Rampa, A.; Piazzi, L.; Bisi, A.; Gobbi, S.; Bartolini, M.; Andrisano, A.; Cavalli, A.; Recanatini, M.; Valenti, P. Cholinesterase inhibitors: xanthostigmine derivatives blocking the acteylcholinesterase-induced β -amyloid aggregation. J. Med. Chem., 2005, 48, 4444-4456.
43. Bartolini, M.; Bertucci, C.; Cavrini, V.; Andrisano, V. β -Amyloid aggregation induced by human acetylcholinesterase: inhibition studies. Biochem. Pharmacol., 2003, 65, 407-416.
44. Camps, P.; Formosa, X.; Galdeano, C.; Muñoz-Torrero, D.; Ramírez, L.; Gómez, E.; Isambert, M.; Lavilla, R.; Badia, A.; Clos, M.V.; Bartolini, M.; Mancini, F.; Andrisano, V.; Arce, M.P.; Rodríguez-Franco, M.I.; Huertas, O.; Dafni, T.; Luque, F.J. Pyrano[3,2-c]quinoline-6-chlorotacrine hybrids as a novel family of acetylcholinesterase-and β -amyloid-directed anti-Alzheimer compounds. J. Med. Chem., 2009, 52, 5365-5379.
45. Rosini, M.; Adrisano, V.; Bartolini, M.; Melchiorre, C. Organic compounds useful for the treatment of Alzheimer's Disease, their use and method of preparation. WO 2006/080043 A2.
46. Torrero, D.M. Acetylcholinesterase inhibitors as disease-modifying therapies for Alzheimer's disease. Curr. Med. Chem., 2008, 15, 2433-2455.
47. Leonetti, F.; Catto, M.; Nicolotti, O.; Pisani, L.; Cappa, A.; Stefanachi, A.; Carotti, A. Homo-and hetero-bivalent edrophonium-like ammonium salts as highly potent, dual binding site AChE inhibitors. Bioorg. Med. Chem., 2008, 16, 7450-7456.
48. Hostettmann, K.; Borloz, A.; Urbain, A.; Marston, A. natural product inhibitors of acetylcholinesterase. Curr. Org. Chem., 2006, 10, 825-847.
49. Sim, M.K.; Chua, M.E. Inhibition of acetylcholinesterase by various opioids. Clin. Exp. Pharmacol. Physiol., 1986, 13, 159-162.
50. Moss, D.E.; Fahrney, D. Anisomycin, acetoxycycloheximide, cycloheximide, and puromycin as inhibitors of rat brain acetylcholinesterase in vitro. J. Neurochem., 1976, 26, 1155-1157.
51. Ellman, G.L.; Courtney, K.D.; Andres, B.J.; Featherstone, R.M. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol., 1961, 7, 88-95.
52. Bolognesi, M.L.; Banzi, R.; Bartolini, M.; Cavalli, A.; Tarozzi, A.; Adrisano, V.; Minarini, A.; Rosini, M.; Tumiatti, V.; Bergamini, C.; Fato, R.; Lenaz, G.; Hrelia, P.; Cattaneo, A.; Recanatini, M.; Melchiorre, C. Novel class of quinone-bearing polyamines as multi-target-directed ligands to combat Alzheimer's disease J. Med. Chem., 2007, 50, 4882-4897.
53. Greenblatt, H.M.; Kryger, G.; Lewis, T.; Silman, I.; Sussman, J.L. Structure of acetylcholinesterase complexed with (-)-galanthamine at 2.3 Å resolution. FEBS Lett., 1999, 463, 321-326.
54. Naiki, H.; Higuchi, K.; Hosokawa, M.; Takeda, T. Fluorometric determination of amyloid fibrils in vitro using the fluorescent dye, thioflavine T. Anal. Biochem., 1989, 177, 244-249.
55. Levine, H. III Thioflavin T interaction with synthetic Alzheimer's disease ß-amyloid peptides: Detection of amyloid aggregation in solution. Protein Sci., 1993, 2, 404-410.
56. PHASE, version 9.0, Schrödinger, LLC, New York, NY 2009.
57. Tawari, N.R.; Bag, S.; Degani, M.S. Pharmacophore mapping of a series of pyrolopyrimidines, indolopyrimidines and their congeners as multidrug-resistance-associated protein (MRP1) modulators. J. Mol. Model., 2008, 14, 911-921.
58. Bag, S.; Tawari, N.R.; Degani, M.S. Insight into inhibitory activity of Mycobacterial dihydrofolate reductase inhibitors by in silico molecular modelling approaches. QSAR Comb. Sci., 2009, 28, 296-311.
59. Xuan-Yu, M.; Hong-Xing, Z.; Mihaly, M.; Meng, C. Molecular docking: a powerful approach for structure-based drug discovery. Curr. Comput. Aided Drug Des., 2011, 7, 146-157.
60. Horacio, P.S.; Wolfgang, W. Optimization methods for virtual screening on novel computational architectures. Curr. Comput. Aided Drug Des., 2011, 7, 44-52.
61. Maestro molecular modeling suit by Schrödinger, LLC, New York, NY, 2009.
62. Galdeano, C.; Viayna, E.; Arroyo, P.; Bidon-Chanal, A.; Blas, J.R.; Muñoz-Torrero, D.; Luque, F.J. Structural Determinants of the Multifunctional Profile of Dual Binding Site Acetylcholinesterase Inhibitors as Anti-Alzheimer Agents. Curr. Pharm. Des., 2010, 16, 2818-2836.
63. Dvir, H.; Wong, D.M.; Harel, M.; Barril, X.; Orozco, M.; Luque, F.J.; Muñoz-Torrero, D.; Camps, P.; Rosenberry, T.L.; Silman, I.; Susman, J.L. 3D structure of Torpedo californica acetylcholinesterase complexed with huprine X at 2.1? resolution: kinetic and molecular dynamic correlates. Biochemistry, 2002, 41, 2970-2981.